Published
POLAR Trial
Maintenance pembrolizumab + olaparib in HRD metastatic pancreatic cancer
Investigator-initiated phase 2 trial of maintenance pembrolizumab + olaparib in biomarker-stratified metastatic pancreatic cancer.
Trials & Programs
Projects
Named clinical trials and translational efforts — each with its own status, design, and outcomes.
Active
Setidegrasib (ASP3082)
First-in-human KRAS G12D targeted protein degrader
First-in-human phase 1 trial of setidegrasib, a first-in-class KRAS G12D targeted protein degrader, in advanced PDAC and NSCLC.
Active
Daraxonrasib (RMC-6236)
Oral RAS(ON) multiselective inhibitor
Phase 1–2 study of daraxonrasib, an oral RAS(ON) multiselective inhibitor, in previously treated RAS-mutated pancreatic cancer; phase 3 RASolute 302 reported in 2026.
Active
RNA Neoantigen Vaccine
Personalized mRNA vaccines targeting tumor neoantigens
Personalized RNA neoantigen vaccine program priming durable, long-lived T-cell responses in pancreatic cancer.